Trial resultsJun 12, 2026137 days ago
Phase 3 LAGOON missed overall survival endpoint for Zepzelca in 2L SCLC
Jazz reported results from its Phase 3 study of Zepzelca (lurbinectedin) for Relapsed (2L) metastatic small cell lung cancer on Jun 12, 2026. The study missed its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
DetailsClinical trial results · also called: readout / topline data
- Company
- Jazz Pharmaceuticals plc JAZZ
- Drug
- Zepzelca (lurbinectedin)
- For
- Relapsed (2L) metastatic small cell lung cancer
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Jun 12, 2026
- Source note
- The PharmaMar-run Phase 3 LAGOON confirmatory trial failed its primary OS endpoint for lurbinectedin, alone or with irinotecan, versus investigator's choice in relapsed second-line small cell lung cancer. Jazz said it would discuss next steps with FDA on post-marketing requirements for the second-line indication.
- Checked
- Checked by a person when it was added
Check the sourcesdon’t take our word for it
- Source: investor.jazzpharma.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- JAZZ headlines on this site
Jazz Pharmaceuticals plc
1 upcoming · 7 past catalysts
More from JAZZ
Jazz expects to report results from its Phase 3 study of Modeyso (dordaviprone) for Recurrent H3 K27M-mutant diffuse glioma in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Modeyso ACTION Phase 3 interim OS analysis · Clinical trial results (readout / topline data)
- Drug
- Modeyso (dordaviprone)
- For
- Recurrent H3 K27M-mutant diffuse glioma
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H1 2027 · the company gave a window, not a day
- Source note
- Q2 2026 results: company anticipates the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, supporting potential full approval.
- Checked
- Checked by a person when it was added
- Verify it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- JAZZ headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page